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Abstract: Osteoarthritis (OA) is the most common rheumatic disease, characterized by progressive
articular cartilage degradation. Raman spectroscopy (RS) has been recently proposed as a label-free
tool to detect molecular changes in musculoskeletal tissues. We used cartilage samples derived from
human femoral heads to perform an ex vivo study of different Raman signals and ratios, related
to major and minor molecular components of articular cartilage, hereby proposed as candidate
optical biomarkers for OA. Validation was performed against the radiological Kellgren–Lawrence
(K-L) grading system, as a gold standard, and cross-validated against sulfated glycosaminoglycans
(sGAGs) and total collagens (Hyp) biochemical contents. Our results showed a significant decrease in
sGAGs (SGAGs, A1063 cm−1/A1004 cm−1) and proteoglycans (PGs, A1375 cm−1/A1004 cm−1) and a
significant increase in collagen disorganization (ColD/F, A1245 cm−1/A1270 cm−1), with OA severity.
These were correlated with sGAGs or Hyp contents, respectively. Moreover, the SGAGs/HA ratio
(A1063 cm−1/A960 cm−1), representing a functional matrix, rich in proteoglycans, to a mineralized
matrix-hydroxyapatite (HA), was significantly lower in OA cartilage (K-L I vs. III–IV, p < 0.05), whilst
the mineralized to collagenous matrix ratio (HA/Col, A960 cm−1/A920 cm−1) increased, being
correlated with K-L. OA samples showed signs of tissue mineralization, supported by the presence of
calcium crystals-related signals, such as phosphate, carbonate, and calcium pyrophosphate dihydrate
(MGP, A960 cm−1/A1004 cm−1, MGC, A1070 cm−1/A1004 cm−1 and A1050 cm−1/A1004 cm−1).
Finally, we observed an increase in lipids ratio (IL, A1450 cm−1/A1670 cm−1) with OA severity. As a
conclusion, we have described the molecular fingerprint of hip cartilage, validating a panel of optical
biomarkers and the potential of RS as a complementary diagnostic tool for OA.
Keywords: optical biomarkers; osteoarthritis; K-L grade; glycosaminoglycans; total collagen; lipids;
calcium crystals
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1. Introduction
Osteoarthritis (OA) is a multifactorial disease that affects movable joints and one of
the main causes of disability worldwide. It manifests as a set of molecular imbalances
followed by physiologic and anatomical alterations of the joint tissues, such as articular
cartilage extracellular matrix (ECM) degradation, subchondral sclerosis, and inflammation
of the synovial membrane, which culminate in illness [1–3].
In its early stages, OA is asymptomatic, which hinders its prompt clinical diagnosis.
In order to clinically assess a patient, pain and mobility questionnaires are performed,
followed by radiography, and in some cases magnetic resonance imaging (MRI), which
allows classification according to OA severity, under different scoring systems [4]. Even
though these imaging techniques are routinely used for OA diagnosis, they present several
disadvantages. On one hand, X-ray analysis is based on the observation of adjacent bone
surface irregularities and remodeling, which limits its scope from moderate to advanced
OA. On the other, MRI’s high cost and incompatibility for some patients, limits its applica-
tion as a regular medical care practice [5]. Together with other unmet needs for successful
diagnosis and treatment, these have spurred the investigation on biomarkers discovery
and validation [6].
Raman spectroscopy (RS) is an optical technique that allows obtaining compositional
information at the molecular level, being a non-invasive and label-free method [7]. It is
based on the inelastic scattering that occurs when a monochromatic light interacts with
the tissue sample analyzed, producing energy variations between the incident radiation
with respect to the reflected. This Raman scattering is characteristic and specific of a
vibrational mode, bond, or molecule present in the tissue composition, producing an unique
molecular fingerprint [8]. Typical Raman spectra are displayed at different intensities with
corresponding wavelength shifts (cm−1) specific to molecular vibrations. Thereafter, raw
data is processed and can be classified according to unsupervised or supervised statistical
methods, allowing sample classification and diagnostic analysis [7].
Recently, RS has been explored in different rheumatologic diseases, including OA,
covering different joint tissues, including articular cartilage, synovium, bone, and to a less
extent, the meniscus, tendons, and ligaments. For each individual tissue, a set of optical
biomarker candidates for OA has been proposed, further supporting RS potential as a
diagnostic method [9–14].
Since the first analysis of human articular cartilage by RS [15], several authors have
reported differences found in specific Raman peaks or ratios related to major ECM com-
ponents that can be associated to molecular events that occur during OA progression.
Such changes can be summarized in alterations on the relative distribution of the col-
lagen secondary structure (amide III, C-N stretching, random coil and α-helix, at 1245
and 1270 cm−1, respectively) [16–18], and the decrease of sulphated glycosaminoglycans
(GAGs) content (OSO3− symmetric stretching, at 1063 cm−1) [15,18]. Additionally, stud-
ies reported the presence of phosphate and carbonate hydroxyapatite peaks (~958 cm−1
and ~1070 cm−1, respectively) in injured cartilage and hypertrophic zones [15,19]. The
occurrence of tissue mineralization and remodeling processes have also been associated
with the presence of the aforementioned Raman peaks, in damaged tissues, on an OA rat
model [20].
So far, RS studies on OA cartilage have covered different anatomical areas of the joint
(tibial plateau and femoral condyle) [17,18,21] but few have referenced histopathological
scoring systems (e.g., the Collins pathological scale) [17]; even on the cellular level, only
one study used chondrocytes isolated from different OA stages, based on the International
Cartilage Repair Society (ICRS) system [18]. In overall, sample sizes used are limited
and there is a lack of validation against clinical gold standards or cross-validation against
biochemical tools [17,22].
In this work, we propose to study the molecular alterations on human cartilage
derived from the femoral heads of a cohort of forty-seven healthy and radiological OA
patients, cross-validated against biochemical assays for sulfated-GAGs (sGAGs) and total
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collagen (Hyp). Raman spectroscopy is further proposed as a complementary diagnostic
tool for OA, through the validation of optical biomarkers.
2. Materials and Methods
2.1. Study Cohort and Sample Collection
Human articular cartilage samples (plugs of 6 mm diameter and ~1 to 1.5 mm thick)
were extracted from the femoral head of 47 donors, 24–48 h, after joint replacement interven-
tion, frozen in liquid nitrogen and stored at −80 ◦C, until further processing. The inclusion
factor was samples from patients with available index femoral head radiography for the
assessment of OA severity, by clinical doctors, according to the Kellgren-Lawrence (K-L)
grading scale as follows: grade 0: no pathological features; grade I: doubtful narrowing of
joint space and possible osteophytic lipping; grade II: definite osteophytes and possible
narrowing of joint space; grade III: moderate multiple osteophytes, definite narrowing
of joint space, some sclerosis, and possible deformity of bony ends, and grade IV: large
osteophytes, marked narrowing of joint space, severe sclerosis, and definite deformity of
bone ends [5]. Six donors were thus classified as healthy (K-L = 0) and forty-one as OA
(K-L ≥ I–IV). The final cohort (Table 1) was composed of cartilage samples from donors
aged between 42 and 94 years (mean age of 72), with a female/male ratio close to 3:2.
Table 1. Demographics and clinical diagnostic of the patients included in this study.
Demographics
Sex
Female (F) n = 27 57.4%
Male (M) n = 20 42.6%
Age Range 42–94 years old
Mean ± SD 72 ± 12 years old
Diagnostic
Radiological grade (K-L) Healthy (K-L 0) n = 6
OA (K-L I–IV) n = 41
2.2. Raman Spectra Obtainment and Data Processing
Raman spectra were collected from the surface of cartilage samples using a WITec
Alpha300R+ Raman spectrometer (WITec focus innovations, Ulm, Germany), equipped
with a Near-Infrared (NIR) laser (λ = 785 nm) with incident laser radiation of 50 mW,
120 scans, 4 cm−1 resolution and an acquisition time of 1 s, to achieve a good signal-to-
noise ratio. Once spectra were acquired, baseline correction and analysis were carried out
using MagicPlot version 2.7 software (Magic Plot Systems, LLC). Briefly, linear baseline
correction was performed by limiting the selected wavenumber intervals, related with
the biochemical vibrations of interest. Peaks’ assignment was then performed based on
available literature. For a quantitative analysis, the main peaks were integrated based on a
Gaussian distribution, adjusting the areas’ sum to the spectral profile in order to predict
signals’ overlaps. An example of the area measurement in an arbitrary spectrum is pre-
sented as supplementary material (Figure S1). Proposed optical biomarkers (Table 2) were
calculated based on the peaks’ area values, and a relative quantification was performed
using phenylalanine (Phe) (1004 cm−1), as normalization peak [15,16,18,19].
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Table 2. Optical biomarker candidates for osteoarthritis (OA) in human cartilage derived from the femoral head.
Optical Biomarker Molecular Component orAssociated Event Acronym Definition





Hydroxyapatite/Collagen HA/Col Bone to collagen
A1039–42 cm−1/A1004 cm−1 Total GAGs TGAGs Total glycosaminoglycans
A1050 cm−1/A1004 cm−1 CPPD CPPD
Calcium pyrophosphate
dihydrate deposits
A1063 cm−1/A1004 cm−1 Sulphated GAGs SGAGs
Sulphated glycosaminoglycans
(OSO3− groups)
A1063 cm−1/A960 cm−1 Sulphated GAGs/Phosphate SGAGs/HA Cartilage to bone
A1070 cm−1/A1004 cm−1 Mineralization—Carbonate Groups MGC
Mineralization grade-carbonated
hydroxyapatite
A1245 cm−1/A1270 cm−1 Defective/Functional Collagen ColD/F
Collagen randomness—as the
relative amount of collagen random
coil (defective Col) to an α-helix
structure (functional Col)
A1375 cm−1/A1004 cm−1 Proteoglycans PGs Proteoglycans
A1450 cm−1/A1668 cm−1 Indirect Lipid Index IL
Relative amount of unspecific lipids
and proteins to the total
protein content
1004 cm−1, Phenylalanine (Phe) peak used for normalization.
2.3. sGAGs and Total Collagen Biochemical Content Analysis
After RS analysis, cartilage samples were frozen at −80 ◦C and lyophilized in a Tel-
star Cryodos (Telstar, Barcelona, Spain), at −0.1 mbar, for 18 h. Explants (10–50 mg)
were digested with papain (2.5 × 10−2 mg/mL) in 0.2 M sodium phosphate buffer
(Na2HPO4−NaH2PO4, pH 6.4), 8 mg/mL sodium acetate, 4 mg/mL EDTA and 0.8 mg/mL
L-cysteine-HCl (all from Sigma-Aldrich, Darmstadt, Germany), at 65 ◦C, for 18 h. The
amount of sulfated GAGs (sGAGs) was quantified using the dimethyl methylene blue
(DMMB) dye-binding assay (Blyscan, Biocolor Ltd., Carrickfergus, UK) with a chondroitin
sulphate standard and normalized against the explants’ wet weight (w.wt). For the quan-
tification of total collagen, an acid hydrolysis of the digested supernatant was performed,
by adding HCl 37% (Panreac AppliChem, Darmstadt, Germany) at a ratio of 1:1, in Teflon-
sealed borosilicate glass vials (Lab Logistics Group, Meckenheim, Germany), at 120 ◦C, for
18 h. The total collagen content was then measured using the hydroxyproline (Hyp) assay
kit (Sigma-Aldrich, Darmstadt, Germany) with hydroxyproline standards and normalized
against each sample’ w.wt. Both sGAGs and Hyp absorbance readings were carried out
for each cartilage sample in duplicate, in 96-well plates, at 656 nm or 560 nm, respectively,
using a Sinergy HTX reader (BioTek, Winooski, VT, USA).
2.4. Statistical Analysis
All statistical analyses were carried out using R statistical open software (version R 3.5.1).
Kruskal–Wallis non-parametric tests with Bonferroni correction were performed. Spear-
man’s correlation coefficients rho were determined in order to compare the proposed
biomarkers versus radiological K-L grade or biochemical parameters, sGAGs and Hyp. All
values are reported ± as means standard deviation (SD). Significance was accepted at a
level of p < 0.05.
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3. Results
3.1. Molecular Alterations during Radiological OA Progression—Raman Spectra Analysis
Raman spectra in the 800–1800 cm−1 region, of human cartilage explants, derived
from healthy donors (K-L 0) and patients with different radiological OA grading (K-L I to
IV) were depicted in Figure 1.
Figure 1. Raman spectra obtained from cartilage explants derived from the femoral heads of pa-
tients with different Kellgren-Lawrence (K-L) radiological OA severity grades (0–IV), obtained
at a λ = 785 nm with incident laser radiation of 50 mW, 120 scans, 4 cm−1 resolution and 1 s
acquisition time.
The main peaks identified, summarized in Table 3, were those obtained at Raman
shifts as follows: 850–880 cm−1, corresponding to the C–C bond stretching of proline (Pro)
and hydroxyproline (Hyp) [16,23]; 920–928 cm−1, corresponding to the C–C stretching
of proline [16]; 940 cm−1, corresponding to both the symmetric stretching mode of the
O–glycosidic bond and the protein C–C stretching [19,23,24]; 1004 cm−1, corresponding to
the aromatic ring stretching of phenylalanine (Phe) [15]; 1042 cm−1, assigned to the C–O–C
stretching, of the pyranose ring of GAGs [23]; 1063 cm−1, assigned to the symmetric stretch-
ing of O–SO3− of sulfated GAGs [15,18,19,23]; 1245–1270 cm−1 doublet, corresponding
to the C–N stretching of amide III, random coil or α-helix structure of collagen, respec-
tively [17]; 1375 cm−1, corresponding to the symmetric stretching of the methyl (–CH3)
group, related to proteoglycans (PGs) [21]; ~1450 cm−1, corresponding to the vibrational
deformation modes (CH2), from lipids and proteins, and ~1670 cm−1, assigned to C=O
stretching of amide I, present in collagen and other proteins [15,16,19].
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Table 3. Raman peaks assignments of articular cartilage molecular fingerprint, obtained from healthy and radiological
OA tissues.














C–O–C α 1–4 glycosidic bond
Collagen
GAGs [16,19,23,24]
954–962 PO43−, symmetric stretching Phosphate hydroxyapatite (HA) [15,19,23,25,26]
1004 Aromatic ring stretchingphenylalanine (Phe) Proteins [15,16,19]
1039–1042 C–O–C stretchingpyranose ring GAGs [23]
1047–1055 P–O–P symmetric stretching CPPD [27]
























1375–1380 CH3 symmetric stretching GAGs, PGs [21]









Collagen and other proteins [15,16,19]
1550–1600 N–H and C–N deformation amide II Proteins [24]
Several differences between healthy and OA cartilage Raman spectra were observed.
For a better comprehension, Figure 2 shows different regions of interest (ROI) and corre-
sponding peaks deconvolution. Grossly, concerning collagen, it was observed a decrease in
the 1270 cm−1 peak, related to a α-helix secondary structure, with respect to ~1245 cm−1,
related to collagen’s random coil configuration (Figure 2A,B) [17,18]. A decrease in peaks
related to PGs (1063 and 1375 cm−1) [21], in severely damaged cartilage (K-L IV) was
observed (Figure 2C,D).
Moreover, the appearance or increase of peaks related to mineralization was observed
in OA cartilage. Different types of inorganic components were found, such as carbonate
compounds in the 1060–1100 cm−1 region (Figure 2C,D, Table 3) and calcium pyrophos-
phate dehydrate deposits (CPP), in the 1020–1055 cm−1 region (Figure 2E,F, Table 3) [27].
An overlap of the carbonated hydroxyapatite peak (type-B carbonate, 1070 cm−1) [21]
with the 1063 cm−1 peak, correspondent to sulfate groups could be observed. Other
carbonate related peaks detected, in OA cartilage (Figure 2D), could be related with amor-
phous carbonate (~1080 cm−1) and crystalline carbonate compounds, as calcium carbonate
(~1090 cm−1) [15,21,25,29–31]. Moreover, an increase of the ~960 cm−1 peak, from hy-
droxyapatite phosphate groups, can be associated with tissue mineralization during OA
progression (Figure 2G,H) [18,19,25,26].
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Figure 2. Deconvolution of peaks of the principal molecular alterations observed in healthy (K-L
0, left column) and radiological OA (K-L IV, right column) cartilage. Regions of interest (ROI) are
depicted as follows, (A,B) 1200–1300 cm−1; (C,D) 1060–1100 cm−1; (E,F) 1020–1055 cm−1; (G,H)
900–1000 cm−1.
3.2. Molecular Alterations during OA Progression—K-L Validation
Ratios related to glycosaminoglycans, i.e., “sulphated GAGs” (SGAGs, A1063 cm−1/
A1004 cm−1), “total GAGs” (TGAGs, A1042 cm−1/ A1004 cm−1) and “PGs” (A1375 cm−1/
A1004 cm−1), showed a decrease with increasing K-L grade (Figure 3). Among these
parameters, only SGAGs and PGs showed statistically significant differences, detected
between healthy and doubtful OA (K-L 0–I grades) with mild to severe OA (K-L II–IV
Diagnostics 2021, 11, 546 8 of 16
grades) as follows, K-L 0 vs. K-L II and IV (p < 0.05) and K-L I vs. K-L II–IV (p < 0.01), K-L
0–I vs. K-L III (p < 0.05), respectively. These results were supported by negative correlations
obtained for SGAGs (rho = −0.632, p < 0.001), PGs (rho = −0.532, p < 0.001) and TGAGs
(rho = −0.324, p = 0.025) (Table 4).
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Figure 3. Quantitative results of Raman ratios related to cartilage components, glycosaminoglycans
(SGAGs, TGAGs, PGs), collagen (ColD/F), lipids (IL) and tissue mineralization (directly related:
CPPD, MGP, MGC and indirectly related: SGAGs/HA and HA/Col) of cartilage, derived from the
femoral head, of healthy (K-L 0) and radiological OA (K-L I–IV) patients. Values are mean ± SD.
Symbols (∆, , ◦, ♦) repres nt individual samples. Significance is indicated as * p < 0.05 and
** p < 0.01.
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Table 4. Spearman’s rho coefficients and p-values for proposed Raman biomarkers and Kellgren–Lawrence (K-L) grading
system. Significance was considered for p < 0.05.
SGAGs TGAGs PGs ColD/F IL CPPD MGP MGC SGAGs/HA HA/Col
rho −0.632 −0.324 −0.532 0.529 0.427 0.191 0.321 0.293 −0.426 0.446
p <0.001 0.025 <0.001 <0.001 0.002 0.219 0.260 0.043 0.005 0.001
Regarding the parameter related to the configuration of collagen fibers, “Defec-
tive/Functional Collagen” ratio (ColD/F, A1245 cm−1/A1270 cm−1) increased with OA
severity, obtaining significant differences between K-L 0–I vs. K-L III (p < 0.05) (Figure 3),
supported by a positive correlation (rho = 0.529, p < 0.001) (Table 4).
The “Indirect Lipid index” ratio (IL, A1450 cm−1/A1668 cm−1) showed an increasing
trend, with significant differences found only between mild and severe radiological OA
(K-L II vs. IV, p < 0.05) (Figure 3) and a correlation with K-L (rho = 0.427, p = 0.002) (Table 4).
For parameters directly related with tissue mineralization, i.e., “Mineralization
—Phosphate Groups” (MGP, A960 cm−1/A1004 cm−1), “Mineralization—Carbonate Groups”
(MGC, A1070 cm−1/A1004 cm−1), “calcium pyrophosphate dihydrate deposits” (CPPD,
A1050 cm−1/A1004 cm−1), we found an increasing trend, in regard with OA severity, for
both MGP and MGC parameters, whilst CPPD presented higher variability (Figure 3). A
weak correlation was found for MGC (rho = 0.293, p = 0.043) (Table 4).
On the other hand, for indirectly related mineralization parameters, an increas-
ing trend with OA severity was found for “Phosphate Hydroxyapatite/Collagen” ratio
(HA/Col, A960 cm−1/A920 cm−1) (Figure 3), indicative of the relative amount of miner-
alized tissue in regard to a collagenous matrix [15], supported by a positive correlation
(rho = 0.446, p = 0.001) (Table 4). An opposite behavior was found in the SGAGs/HA ratio
(A1063 cm−1/A960 cm−1), indicative of the relative amount of functional extracellular ma-
trix, rich in GAGs, with respect to the mineralized matrix [15], with significant differences
between K-L I and K-L III–IV (p < 0.05) (Figure 3) and a negative correlation (rho = −0.426,
p = 0.005) (Table 4).
3.3. Molecular Alterations during OA Progression—Biochemical Cross-Validation
The sGAGs content obtained biochemically was observed to significantly decrease
with the progression of cartilage degradation, from values of 41.10 ± 10.52 (K-L I) to
26.49 ± 12.42 (K-L II) and 29.69 ± 11.16 µg/mg w.wt (K-L III) (both p < 0.05) and
24.26 ± 10.68 µg/mg w.wt (K-L IV, p < 0.01) (Figure 4A). This finding is consistent with
a decrease observed in the proposed Raman biomarkers related with GAGs and PGs
(Figure 2).
Figure 4. Biochemical content of sGAGs (A) and total collagens (Hyp) (B) of articular cartilage with
different Kellgren–Lawrence (K-L) grades. Values are mean ± SD. Dots represent individual samples.
Significance is indicated as * p < 0.05 and ** p < 0.01.
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Furthermore, sGAGs content was found to be positively correlated with the Raman
parameters SGAGs (A1063 cm−c/1004 cm−1) and PGs (A1375 cm−/1004 cm−1), obtaining
a higher value for SGAGs, which is directly related to sulphate groups (rho = 0.6830), when
compared with PGs (rho = 0.5952) (both p < 0.0001) (Figure 5). No significant correlation
was detected between sGAGs biochemical content and the TGAGs parameter (rho = 0.2659,
p = 0.075) (data not shown).
Figure 5. Correlations obtained between sGAGs and total collagens (Hyp) biochemical content and
related optical biomarkers, SGAGs (A1063 cm−1/1004 cm−1) and PGs (A1375 cm−1/1004 cm−1),
and ColD/F (A1425 cm−1/1270 cm−1) and H/Col (A960 cm−1/920 cm−1), respectively. Spearman’s
rho coefficients and p-values are indicated. Significance was considered for p < 0.05.
Regarding total collagens content obtained biochemically, a significant decrease was
observed with OA severity, namely, K-L 0 and I vs. K-L IV (Hyp = 23.47 ± 14.2 and
18.71 ± 5.81 vs. 12.71 ± 4.87 µg/mg w.wt, p < 0.05), K-L I vs. K-L II (Hyp = 18.71 ± 5.81
vs. 10.65 ± 3.33 µg/mg w.wt, p < 0.01) and K-L II vs. K-L III (Hyp = 10.65 ± 3.33
vs. 15.88 ± 1.43 µg/mg w.wt, p < 0.01) (Figure 4B). Hyp was found to be negatively
correlated with Raman biomarkers ColD/F (A1245 cm−1/A12070 cm−1) and HA/Col
(A960 cm−1/A920 cm−1), with rho = −0.2894 (p = 0.0485) and rho = −0.3168 (p = 0.0340),
respectively (Figure 5). These results suggest that Hyp biochemical content was lower in
cartilage samples where both a greater relative disorganization of collagen and bone to
collagenous matrix ratio were observed, in the course of OA severity (Figure 2 ColD/F and
HA/Col, respectively).
4. Discussion
OA is a complex and multifactorial disease characterized by major changes that
succinctly consist on the disorganization of the articular cartilage, edema, chondrocyte
apoptosis, tissue loss, and subchondral bone changes [2]. Even though structural, cellular,
and molecular processes during cartilage degradation have been thoroughly investigated,
OA pathogenesis is far from being understood. As such, early diagnosis, biomarkers
validation and personalized treatments are still some of its major unmet needs [32,33].
Raman spectroscopy has been previously used to describe the molecular fingerprint
of articular cartilage derived from different joint tissues [15,16,18,19,23]. However, there is
still a lack of consistent studies that can validate the use of Raman signals or derived ratios
Diagnostics 2021, 11, 546 11 of 16
for the detection and follow-up of molecular changes in the onset and progression of OA.
For this study, focused on hip OA, we have selected and proposed an optical biomarker
panel, based on a previous literature review, considering representative parameters, related
with major and minor cartilage ECM components [13].
From the parameters related with GAGs, we demonstrated negative correlations
between SGAGs and PGs with radiological OA severity. These were both cross-validated
against sGAGs biochemical content, which support the decrease in proteoglycans that
occurs in OA cartilage [34]. SGAGs ratio hereby proposed as a candidate biomarker was
previously studied by Kumar et al., obtaining similar results regarding the ICRS grading
system [18]. It is worth noting that, from all the candidate biomarkers, SGAGs was the
only where a significant difference was found between healthy–doubtful OA and moderate
radiological grade (K-L 0–I vs. II) (Figure 3). The lack of differences between healthy
cartilage samples and those in early stages of OA may be due to compensatory synthesis
mechanisms of chondrocytes in response to initial damage [34]. Moreover, SGAGs, being
directly related to sulphate groups, has potential in assessing the sulphation loss in the
cartilaginous tissue during its degradation [35]. Water content was also found increased,
although this was not significant (data not shown).
Considering other major component of cartilage ECM, we have studied the ColD/F
parameter, proposed by other authors, to characterize the disorganization of the relative
structure of collagen [17,18]. This parameter that significantly increased with OA severity,
also correlated with K-L grade. The observed increase in the random coil collagen structure
signal (i.e., defective collagen), could be indicative of denaturation or metabolic changes in
the collagen synthesis process. OA chondrocytes have been described to synthetize type-X
collagen in hypertrophic cartilage and type-VI collagen in interterritorial zones [34,36].
These two types of collagen have large non-helical terminal domains, and considerably
smaller α-helix domains than those of type-II collagen (460 and 200 amino acids respectively,
compared to 1000 amino acids) [37,38]. Therefore, the increase in the ColD/F parameter
could be due to the synthesis of both type-X and -VI collagens.
Although previous studies showed total collagens content to be either increased
or not altered during OA, by synthesis/degradation processes [39–42], in our case, Hyp
biochemical content significantly decreased with OA severity, which could be related to the
stability of type-II collagen triple helix structure domains [43]. Furthermore, the association
of this amino acid with the stability of the collagen structure was confirmed, finding a weak,
but significant correlation, indicating a greater relative disorganization of the collagen
fibers (higher ColD/F values) with a decrease in Hyp residues.
HA/Col showed a negative correlation with Hyp content, indicating a lower relative
collagen content with an increasing mineralization, which could be related to nucleation
and crystal deposition processes around collagen fibers. The mineralization process could
also be favored by a decrease in proteoglycans and sGAGs in cartilage ECM during OA
progression [44,45], supported in our case, by a decrease in the SGAGs/HA parameter.
Mineralization and tissue remodeling are processes that occur during OA progression.
Basic calcium phosphate (BCP), such as hydroxyapatite (HA), and calcium pyrophosphate
dihydrate (CPP) are commonly deposited in OA and aging cartilage and can directly
promote the production of catabolic and pro-inflammatory cytokines and enzymes by
chondrocytes and synovial cells [46]. The pathogenic mechanism of calcium crystals
deposition is still not fully elucidated and calcium-containing crystal deposition diseases
are commonly underdiagnosed.
Even though both crystal types have been shown to coexist in cartilage [47], other
authors have rarely found them in the same articular tissue (condyle vs. tibial plateau)
or zonal distribution (lateral vs. medial compartments) [44]. In our study, we detected
the concomitant presence of spectral bands for molecular functional groups associated
with both BCP (MGP and MGC) and CPPD, in 68% of the samples (data not shown).
Even though CPPD was present in the majority of samples (87.5%) (data not shown), its
deposition was not correlated with OA severity.
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Indeed, others have demonstrated that in some instances CPPD in cartilage middle
zone can accumulate in the absence of cartilage lesions. Although the same authors also
reported superficial zone crystal deposition to be linked with cartilage lesions, suggesting
an intimate association between metabolically altered and fissured cartilage with crystal
nucleation that worsens the tissue mechanical damage [48].
The relatively unique capacity of chondrocytes to produce extracellular inorganic
pyrophosphate is linked to the promotion of chondrocalcinosis [49]. In our case, three cases
of chondrocalcinosis were confirmed during radiography examination, from which, two
samples had the highest CPPD (K-L I) or MGC (K-L III) ratios (Figure 3), although these
could also be related to other degradation processes associated with age [50].
On the other hand, only HA-related signals (phosphate—MGP and carbonate—MGC)
showed an increasing trend with OA severity, supported by a significant correlation for
the latest. A relation between BCP crystals presence in the synovial fluid of patients
with radiologic knee OA has previously been shown [51]. BCP crystals have also been
associated with secondary forms of arthropathies or calcific periarthritis [46]. In our cohort,
we found one sample, that concomitantly presented one of the highest MGC and CPPD
ratios (K-L IV, Figure 3), to be a diagnosed case of psoriatic arthritis. These results support
further investigation on the potential of RS in the diagnosis of calcium crystal deposition
musculoskeletal diseases, complemented with other techniques, such as histology and
polarized light microscopy, in order to elucidate the contribution of crystals deposition in
cartilage degradation and remodeling processes [52].
Finally, when considering ECM minor components, such as lipids, this is the first
study that reports IL for cartilage molecular characterization, based on Raman peaks
previously described for other tissues [53,54]. We observed a significant increase of the IL
parameter, for moderate and severe radiological hip OA samples, supported by a positive
correlation. These results could be related to an accumulation of lipids in OA cartilage
and concomitant protein low abundance due to ECM proteolysis, as described by mass
spectrometry [55,56]. Others have shown in cellular studies using chondrocytes an increase
in lipid deposition, by considering other Raman signals attributed to lipids (~1304 cm−1)
with the advancement of OA [28]. Nonetheless, more studies are needed to elucidate the
role of lipid deposition in OA progression. Other variable to have into account is body
mass index (BMI), which has been shown to influence on the quantification of the peak
~1450 cm−1 [54]. Being obesity a risk factor for OA, BMI values could be considered in
future analyses. Unfortunately, these data were not available for the current study.
Even though this study sheds light in the potential of optical biomarkers for OA
diagnosis, it presents some limitations. This study constitutes the biggest cohort on hip-OA
with RS to date, although due to lack of access to radiographies from samples derived
from healthy tissue, only six samples were available. Moreover, some of these samples,
even though found no radiological signs of OA, already presented some macroscopically
identified lesions. In contrast and due to access derived from replacement surgeries, an
over-representation of K-L IV grade samples was obtained.
Another limitation was that cartilage samples were not always obtained from the
same compartment of the hip and thus our cohort comprises samples from both load and
non-load areas that have been associated with different RS profiles [17]. Nevertheless,
we conducted a comparison between RS parameters in cartilage derived from lesion and
adjacent sites and we could only find significant differences for SGAGs and HA/Col in
K-L II samples (data not shown), which can be an indicative that molecular alterations
could already be predicted in adjacent and macroscopically intact cartilage. This finding is
noteworthy when considering future translation of RS for OA diagnosis in clinical settings,
already being tested in vivo under laser coupling with fiber optic probe systems [15,57,58].
In summary, described findings in this study support the association of the different
optical biomarker candidates with OA-cartilage molecular changes that include, a decrease
in proteoglycans that can be related to the action of aggrecanases and metalloproteases
(MMP) and a lower expression of aggrecan by chondrocytes [34,59], sulphation loss [40],
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alterations or denaturation of the collagen network [39,60], and nucleation of calcium
crystals around altered collagen fibers [45,61].
5. Conclusions
We have successfully described the molecular fingerprint of human articular cartilage
derived from the femoral head of healthy and radiological OA patients. Our results support
SGAGs, PGs, and ColD/F as optical OA biomarker candidates, obtaining significant
correlations with K-L grade as gold standard and cross-validated against sGAGs and Hyp
biochemical contents. IL and calcium-related signals (MGP, MCP, and CPPD) have also
shown potential and need further validation for their role in elucidating tissue remodeling
and mineralization processes during OA. Finally, this study supports Raman spectroscopy
application as a diagnostic complementary tool for hip OA.
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